<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04671693</url>
  </required_header>
  <id_info>
    <org_study_id>PASCA</org_study_id>
    <secondary_id>2020-A01130-39</secondary_id>
    <nct_id>NCT04671693</nct_id>
  </id_info>
  <brief_title>A Post-treatment Program to Identify and Manage Complications Related to Oncology or Hematology Treatments in Cancer Survivors.</brief_title>
  <acronym>PASCA</acronym>
  <official_title>Study of Complications Related to Treatments in Adults Aged 18 to 65 Years Old Responding to a First Treatment in Oncology or Onco-hematology and Participating in the PASCA (PArcours de Santé au Cours du CAncer) Post-treatment Program.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Leon Berard</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Malakoff-Humanis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fondation Apicil</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fédération Leucémie Espoir</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Biogaran</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Le défi Anthony</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Leon Berard</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      INTRODUCTION: Approximately 44% of cancer survivors experience a deteriorated quality of life&#xD;
      5 years after diagnosis due to late onset of complications related to cancer treatments. The&#xD;
      objective of the study is to evaluate the incidence rates of treatment-related complications,&#xD;
      identify sub-clinical abnormalities and risk factors in patients participating in the PASCA&#xD;
      post-treatment program.&#xD;
&#xD;
      METHOD: PASCA is a single-center, interventional cohort study of adult patients who received&#xD;
      at least chemotherapy and with a complete remission to a testicular germ cell tumor, primary&#xD;
      non-metastatic invasive breast carcinoma, high-grade soft tissue sarcoma, osteosarcoma,&#xD;
      Ewing's sarcoma, acute myeloid leukemia, Hodgkin's or aggressive non-Hodgkin's lymphoma. Four&#xD;
      assessment visits will be scheduled at 1 month (T1), 6 months (T2), 24 months (T3) and 60&#xD;
      months (T4) after completion of treatment. During these visits, 22 complications will be&#xD;
      screened and follow-up care will be systematically offered to the health professional&#xD;
      concerned by the complication in case of a positive result. The screening will contain the&#xD;
      following elements: screening self-questionnaires, quality of life questionnaire, 12&#xD;
      biological parameters, a urinalysis evaluating hematuria, proteinuria, and leukocyturia, a&#xD;
      spirometry, an electrocardiogram, 5 tests evaluating physical condition, vital signs and the&#xD;
      perimetric measurement between both arms.&#xD;
&#xD;
      DISCUSSION: This systematic screening could highlight a number of complications occurring&#xD;
      after cancer treatments. Sub-clinical abnormalities and new risk factors could also be&#xD;
      identified. This new organization of care could improve the quality of life of adult cancer&#xD;
      survivors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 24, 2020</start_date>
  <completion_date type="Anticipated">April 24, 2028</completion_date>
  <primary_completion_date type="Anticipated">January 24, 2028</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>All patients in the study will benefit from the PASCA post-treatment program with 4 visits : at 1 month (T1), 6 month (T2), 24 month (T3) and 60 month (T4) after the end of treatment.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of social precariousness</measure>
    <time_frame>Month 1</time_frame>
    <description>Diagnosed by a social worker</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline return to work issues incidence at 60 months</measure>
    <time_frame>Month 1, Month 6, Month 24, Month 60</time_frame>
    <description>Diagnosed by a social worker</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline cognitive problems incidence at 60 months</measure>
    <time_frame>Month 1, Month 6, Month 24, Month 60</time_frame>
    <description>Diagnosed by a neurologist</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline anxiety crises incidence at 60 months</measure>
    <time_frame>Month 1, Month 6, Month 24, Month 60</time_frame>
    <description>Diagnosed by a psychologist or psychiatrist</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline depressive events incidence at 60 months</measure>
    <time_frame>Month 1, Month 6, Month 24, Month 60</time_frame>
    <description>Questionnaire &quot;HADS-D&quot; (Hospital Anxiety and Depression scale)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline chronic fatigue incidence at 60 months</measure>
    <time_frame>Month 1, Month 6, Month 24, Month 60</time_frame>
    <description>Questionnaire &quot;MFI-20&quot; (Multidimensional Fatigue Inventory)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline physical deconditioning incidence at 60 months</measure>
    <time_frame>Month 1, Month 6, Month 24, Month 60</time_frame>
    <description>A value below the lower limit on at least two of the following physical tests&#xD;
Six-Minute Walk Test (6MWT) (meters)&#xD;
Hand Grip Strength Test (Kg)&#xD;
Five Times Sit to Stand Test (number)&#xD;
Flamingo Test (sec)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline overweight/obesity incidence at 60 months</measure>
    <time_frame>Month 1, Month 6, Month 24, Month 60</time_frame>
    <description>BMI&#xD;
Waist circumference</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline chronic pain incidence at 60 months</measure>
    <time_frame>Month 1, Month 6, Month 24, Month 60</time_frame>
    <description>Duration of pain&#xD;
Questionnaire &quot;DN4&quot; (Douleur Neuropathique en 4 questions)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline dermatological disorders incidence at 60 months</measure>
    <time_frame>Month 1, Month 6, Month 24, Month 60</time_frame>
    <description>Common Terminology Criteria for Adverse Events (CTCAE) v5</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline gastrointestinal disorders incidence at 60 months</measure>
    <time_frame>Month 1, Month 6, Month 24, Month 60</time_frame>
    <description>Common Terminology Criteria for Adverse Events (CTCAE) v5</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline sexual disorders incidence at 60 months</measure>
    <time_frame>Month 1, Month 6, Month 24, Month 60</time_frame>
    <description>Questionnaire &quot;Sexualité VICAN5&quot;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline hypogonadism incidence at 60 months</measure>
    <time_frame>Month 1, Month 6, Month 24, Month 60</time_frame>
    <description>Presence of clinical signs as defined by the International Society for Sexual Medicine&#xD;
A value below the lower limit on at least one of the following blood assay:&#xD;
level of total testosterone&#xD;
level of bioavailable testosterone</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from 24 months premature ovarian failure incidence at 60 months</measure>
    <time_frame>Month 24, Month 60</time_frame>
    <description>level of Follicle stimulating hormone&#xD;
level of estradiol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline osteoporosis incidence at 60 months</measure>
    <time_frame>Month 1, Month 6, Month 24, Month 60</time_frame>
    <description>T-score evaluated by osteodensitometry, on the lumbar spine and upper end of the femur</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline chronic kidney failure incidence at 60 months</measure>
    <time_frame>Month 1, Month 6, Month 24, Month 60</time_frame>
    <description>Diagnosed on the basis of 2 blood tests within 3 months using the same technique showing a decrease in GFR to &lt; 60ml/min/1.73m2, estimated from creatinine levels using the CKD-EPI equation (Chronic Kidney Disease EPIdemiology collaboration, Levey, 2009), albuminuria or proteinuria positive, hematuria, leukocyturia &gt; 10/mm3, or morphological abnormality on renal ultrasound.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline heart failure incidence at 60 months</measure>
    <time_frame>Month 1, Month 6, Month 24, Month 60</time_frame>
    <description>Diagnosed by a cardiologist with an echocardiography performing the Left Ventricular Ejection Fraction (LVEF) estimate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline coronary heart disease incidence at 60 months</measure>
    <time_frame>Month 1, Month 6, Month 24, Month 60</time_frame>
    <description>Diagnosed by a cardiologist conducting at least an interrogation with clinical examination, an estimation of pre-test probability of coronary artery disease</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline respiratory failure incidence at 60 months</measure>
    <time_frame>Month 1, Month 6, Month 24, Month 60</time_frame>
    <description>Forced Vital Capacity&#xD;
Forced expiratory volume in 1 second&#xD;
Vital capacity&#xD;
Tiffeneau ratio&#xD;
Peak expiratory flow&#xD;
Total lung capacity&#xD;
Diffusing Capacity Of The Lungs For Carbon Monoxide</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline hypothyroidism incidence at 60 months</measure>
    <time_frame>Month 1, Month 6, Month 24, Month 60</time_frame>
    <description>level of thyroid-stimulating hormone&#xD;
level of total thyroxine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline lymphedema incidence at 60 months</measure>
    <time_frame>Month 1, Month 6, Month 24, Month 60</time_frame>
    <description>Diagnosed by a vascular physician with a perimetric measurement of arms and forearms</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline second primary cancers incidence at 60 months</measure>
    <time_frame>Month 1, Month 6, Month 24, Month 60</time_frame>
    <description>Pathology report recorded in the patient file.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the PASCA program: referrals made through the network</measure>
    <time_frame>Month 6, Month 24, Month 60</time_frame>
    <description>Number of referrals made through the network (attending physicians, specialist physicians, supportive care services or other health professionals)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the PASCA program: time between patient referral and completion of the first consultation</measure>
    <time_frame>Month 6, Month 24, Month 60</time_frame>
    <description>Average time (days) between patient referral and completion of the first consultation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the PASCA program: patient characteristics</measure>
    <time_frame>Month 1, Month 6, Month 24, Month 60</time_frame>
    <description>Comorbidities at diagnosis&#xD;
Tumor classification&#xD;
cytogenetics mutations&#xD;
types and doses of each cancer treatments&#xD;
ratio of the number of patients included / number of eligible patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the impact of program adherence on the evolution of the number of complications detected over time</measure>
    <time_frame>Month 6, Month 24, Month 60</time_frame>
    <description>Measurement of the association between program adherence rate and the number of complications detected over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the impact of program adherence on quality of life.</measure>
    <time_frame>Month 6, Month 24, Month 60</time_frame>
    <description>Measurement of the association between program adherence rate and the overall score on the secondary dimensions of quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of the PASCA network : characteristics of health professionals sensitive to the post-treatment issues.</measure>
    <time_frame>Month 6, Month 24, Month 60</time_frame>
    <description>number of health professionals affiliated with the network&#xD;
type of health professionals affiliated with the network&#xD;
distribution over the Auvergne-Rhône-Alpes region according to medical speciality and department</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identification of risk factors associated with complications occurring during follow-up.</measure>
    <time_frame>Month 1, Month 6, Month 24, Month 60</time_frame>
    <description>Measurement of the association between suspected risk factors and the occurrence of a type of complication, during the duration of follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of the Global Longitudinal Strain</measure>
    <time_frame>Month 6, Month 24, Month 60</time_frame>
    <description>Evolution of the Global Longitudinal Strain in absolute value, relative to a later value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of the Left Ventricular Ejection Fraction</measure>
    <time_frame>Month 6, Month 24, Month 60</time_frame>
    <description>Evolution of the Left Ventricular Ejection Fraction relative to a later value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of the troponin I level</measure>
    <time_frame>Month 6, Month 24, Month 60</time_frame>
    <description>Evolution of the troponin I level relative to a later value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of the Glomerular Filtration Rate</measure>
    <time_frame>Month 6, Month 24, Month 60</time_frame>
    <description>Evolution of the Glomerular Filtration Rate estimated by the CKD-EPI equation relative to a later value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of spirometry values</measure>
    <time_frame>Month 6, Month 24, Month 60</time_frame>
    <description>Evolution of spirometry values relative to later values :&#xD;
Forced Vital Capacity&#xD;
Forced expiratory volume in 1 second&#xD;
Vital capacity&#xD;
Tiffeneau ratio&#xD;
Peak expiratory flow</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of diabetes mellitus</measure>
    <time_frame>Month 6, Month 24, Month 60</time_frame>
    <description>Level of fasting blood glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of untreated high blood pressure</measure>
    <time_frame>Month 6, Month 24, Month 60</time_frame>
    <description>Measure of systolic blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of hypertriglyceridemia</measure>
    <time_frame>Month 6, Month 24, Month 60</time_frame>
    <description>Level of triglyceridemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of hyper-LDL-cholesterolemia</measure>
    <time_frame>Month 6, Month 24, Month 60</time_frame>
    <description>Level of LDL-cholesterolemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of low level of physical activity</measure>
    <time_frame>Month 6, Month 24, Month 60</time_frame>
    <description>Questionnaire &quot;Godin-Shephard Leisure-Time Physical Activity&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of insufficiency / deficiency of 25(OH) vitamin D (D2+D3)</measure>
    <time_frame>Month 6, Month 24, Month 60</time_frame>
    <description>Level of 25(OH) vitamin D (D2+D3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of carcinogenic products consumption (tobacco, alcohol, cannabis)</measure>
    <time_frame>Month 1, Month 6, Month 24, Month 60</time_frame>
    <description>Number of packages years&#xD;
Questionnaire &quot;DETA-Cage&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the Progression-free survival</measure>
    <time_frame>Month 6, Month 24, Month 60</time_frame>
    <description>Evaluation of the Progression-free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the Survival without an increase in the number of complications, among those studied</measure>
    <time_frame>Month 6, Month 24, Month 60</time_frame>
    <description>Evaluation of the Survival without an increase in the number of complications, among those studied</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the event-free survival</measure>
    <time_frame>Month 6, Month 24, Month 60</time_frame>
    <description>Evaluation of the event-free survival</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">858</enrollment>
  <condition>Late Effects</condition>
  <condition>Testicular Germ Cell Tumor Mixed</condition>
  <condition>Non-Metastatic Breast Carcinoma</condition>
  <condition>Soft Tissue Sarcoma, Adult, Stage IIC</condition>
  <condition>Osteosarcoma</condition>
  <condition>Ewing's Sarcoma</condition>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Hodgkin Disease</condition>
  <condition>Non Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>PASCA intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PASCA intervention</intervention_name>
    <description>At each study visit (T1 = 1 month, T2 = 6 months, T3 = 24 months, T4 = 60 months), an exhaustive screening of complications as well as associated sub-clinical abnormalities and risk factors previously identified as such in the literature, will be conducted.&#xD;
Management of complications consists of referring the patient to a healthcare professional belonging to the PASCA network based on the test results. Referral is defined by referring to pre-established decision trees. It is made to a specialist physician, a health professional from the paramedical field or the patient's general practitioner who confirms the diagnosis if necessary and initiates the patient's care and follow-up. These patients also receive their usual follow-up in the context of their tumor pathology in oncology and onco-hematology.</description>
    <arm_group_label>PASCA intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 years old and ≤ 65 years old.&#xD;
&#xD;
          2. Follow-up at the Léon Bérard center&#xD;
&#xD;
          3. Treated by chemotherapy for one of the following pathologies, and confirmed by the&#xD;
             reference diagnostic technique :&#xD;
&#xD;
               -  acute myeloid leukemia;&#xD;
&#xD;
               -  Hodgkin's lymphoma;&#xD;
&#xD;
               -  aggressive non-Hodgkin's lymphoma;&#xD;
&#xD;
               -  primary non-metastatic invasive breast carcinoma;&#xD;
&#xD;
               -  testicular germ cell tumor treated with at least 3 courses of BEP (bleomycin,&#xD;
                  etoposide, cisplatin), 4 courses of EP (etoposide, cisplatin) or 4 courses of VIP&#xD;
                  (etoposide, ifosfamide, cisplatin) received;&#xD;
&#xD;
               -  high-grade soft tissue sarcoma, osteosarcoma or Ewing's sarcoma.&#xD;
&#xD;
          4. As a complete response at the end of treatment consultation. If end-of-treatment&#xD;
             evaluation is not available at the time of inclusion: as an assumed complete response&#xD;
             in the opinion of the investigator based on the previous assessment of response.&#xD;
&#xD;
          5. Whose capacity to practice an adapted physical activity will have been certified by a&#xD;
             medical certificate issued by the investigating physician, the general practitioner or&#xD;
             the referring physician.&#xD;
&#xD;
          6. Able to understand, read and write French.&#xD;
&#xD;
          7. Available and willing to participate in the project throughout the duration of the&#xD;
             study.&#xD;
&#xD;
          8. Living in the Auvergne-Rhône-Alpes region or in the department of Saône-et-Loire&#xD;
&#xD;
          9. Affiliated with a health insurance plan.&#xD;
&#xD;
         10. Having declared an attending physician.&#xD;
&#xD;
         11. Having signed and dated the informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. With a history of malignancy other than basal cell skin cancer.&#xD;
&#xD;
          2. Cannot be followed for medical, social, family, geographical or psychological reasons&#xD;
             for the duration of the study.&#xD;
&#xD;
          3. Participating in other studies that could impact on the evaluation of the judgement&#xD;
             criteria.&#xD;
&#xD;
          4. Deprived of liberty by judicial or administrative decision.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mauricette MICHALLET, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Leon Berard</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Romain BUONO, PharmD, MPH</last_name>
    <phone>+33469856358</phone>
    <email>romain.buono@lyon.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Meyssane DJEBALI, Msc</last_name>
    <phone>+33469856358</phone>
    <email>meyssane.djebali@lyon.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mauricette MICHALLET, MD</last_name>
      <phone>+33469856358</phone>
      <email>mauricette.michallet@lyon.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Yves BLAY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas BACHELOT</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Helen BOYLE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aude FLECHON</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christelle DE LA FOUCHARDIERE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre-Etienne HEUDEL</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre SAINTIGNY</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olivier TREDAN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philippe TOUSSAINT</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mehdi BRAHMI</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alice BONNEVILLE-LEVARD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Armelle DUFRESNE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne-Sophie MICHALLET</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Clemence SANTANA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Béatrice FERVERS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie Adele DAMMACCO</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christelle FAURE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-François BRANTUS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mellie HEINEMANN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Léa ROSSI</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Violette MESDAG</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Raphaelle PICARD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicolas CHOPIN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mélodie CARBONNAUX</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philippe REY</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yann GUILLERMIN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laure LEBRAS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emmanuelle NICOLAS-VIRELIZIER</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amine BELHABRI</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Souad ASSAAD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Franck-Emmanuel NICOLINI</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Benoite MERY</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jessica SERRAND</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Séverine RACADOT</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Waisse WAISSI</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aude VISY</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paul POU</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Clémence BONDU</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ronan TANGUY</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cécile LAUDE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Coralie MONCHARMONT</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christian CARRIE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre MEEUS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>François GOUIN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Armelle VINCENEUX</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>December 3, 2020</study_first_submitted>
  <study_first_submitted_qc>December 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 17, 2020</study_first_posted>
  <last_update_submitted>February 4, 2021</last_update_submitted>
  <last_update_submitted_qc>February 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Late Effects</keyword>
  <keyword>Survivors</keyword>
  <keyword>Adults</keyword>
  <keyword>Screening</keyword>
  <keyword>Tertiary prevention</keyword>
  <keyword>Testicular Germ Cell Tumor Mixed</keyword>
  <keyword>Non-Metastatic Breast Carcinoma</keyword>
  <keyword>Soft Tissue Sarcoma</keyword>
  <keyword>Osteosarcoma</keyword>
  <keyword>Ewing's Sarcoma</keyword>
  <keyword>Acute Myeloid Leukemia</keyword>
  <keyword>Hodgkin Disease</keyword>
  <keyword>Non Hodgkin Lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Neoplasms, Germ Cell and Embryonal</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Osteosarcoma</mesh_term>
    <mesh_term>Sarcoma, Ewing</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

